pCR Associated With TILs in HER2+ Breast Cancer

Share this content:
High baseline tumor-infiltrating lymphocytes are associated with a higher likelihood of achieving pCR in HER2-positive breast cancer regardless of the neoadjuvant chemotherapy regimen.
High baseline tumor-infiltrating lymphocytes are associated with a higher likelihood of achieving pCR in HER2-positive breast cancer regardless of the neoadjuvant chemotherapy regimen.

High baseline tumor-infiltrating lymphocytes (TILs) are associated with a higher likelihood of achieving a pathologic complete response (pCR) in HER2-positive breast cancer regardless of the neoadjuvant chemotherapy regimen, according to a meta-analysis published in Cancer Treatment Reviews.1

High baseline TILs were previously associated with higher pCR rates after neoadjuvant anthracycline- or taxane-based chemotherapy. This analysis evaluated whether patients with high baseline TILs would benefit more from the immune-modulating effects of trastuzumab rather than chemotherapy.

The meta-analysis included data from 5 randomized controlled trials including 1256 women with HER2-positive breast cancer who received neoadjuvant chemotherapy plus trastuzumab and/or lapatinib.

High baseline TILs were associated with a significantly greater pCR rate (odds ratio [OR], 2.46; 95% CI, 1.36-4.43; P = .003), though high heterogeneity was noted (I2 = 74.8%; P = .003), indicating inconsistency across the trials.

This benefit was observed regardless of the neoadjuvant regimen, with no significant difference between regimens. The OR for pCR was 1.90 with trastuzumab, 1.79 with lapatinib, and 3.06 with the combination. The OR for pCR with an anthracycline plus taxane chemotherapy and anti-HER2 agent(s) was 2.84.

RELATED: Genetics and Breast Cancer Subtypes Among African American and Caucasian Patients

According to the authors, this study “confirmed the association between high TIL at baseline and increased pCR rates after neoadjuvant treatments with chemotherapy and anti-HER2 agent(s).” They noted that more studies are needed to determine the role of TILs in biopsies and residual disease for guiding treatment decisions.

Reference

  1. Solinas C, Ceppi M, Lambertini M, et al. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trials. Cancer Treat Rev. In press.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters